Foley Hoag LLP represented Alcyone Therapeutics on the deal. Alcyone Therapeutics (Alcyone) announced the negotiation of a license and collaboration agreement with Biogen Inc. (Nasdaq: BIIB) to...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Vergent Bioscience, Inc. on the deal. Vergent Bioscience, Inc. (“Vergent”), a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced a $21.5 million Series...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Satellite Bio on the deal. Satellite Bio, a regenerative medicine company raised $110 million in Seed and Series A funding. The recent Series A...
You must be a Standard 1 Year member to access this content.
Foley Hoag advised RedShift BioAnalytics on the deal. RedShift BioAnalytics Inc. (RedShiftBio), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in...
You must be a Standard 1 Year member to access this content.
Foley Hoag advised H.I.G. BioHealth Partners and Accelmed Partners on the deal. H.I.G. BioHealth Partners and Accelmed Partners acted as new investors and co-leads in the...
You must be a Standard 1 Year member to access this content.
Foley Hoag advised Alcyone Therapeutics on the deal. Alcyone Therapeutics, a Lowell, Massachusetts-based biotechnology company pioneering next-generation precision central nervous system (CNS) therapies, closed $23 million in...
You must be a Standard 1 Year member to access this content.
